Title : Effective drug treatment identified by in vivo screening in a transplantable patient-derived xenograft model of chronic myelomonocytic leukemia.

Pub. Date : 2020 Nov

PMID : 32576961






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The novel combination treatment with azacitidine and the MEK-inhibitor trametinib additively inhibited ERK-phosphorylation and thus depleted the signal from mutated NRAS. trametinib neuroblastoma ras oncogene Mus musculus
2 Thus, we identified the combination of azacitidine and trametinib as an effective treatment in NRAS-mutated CMML and propose its clinical development. trametinib neuroblastoma ras oncogene Mus musculus